The EMA has announced that it will launch a new section of its IRIS online platform for drug developers seeking scientific advice, starting Oct. 19.

IRIS was launched in 2018 to assist sponsors with Orphan Drug designations, but the agency has been expanding it to cover other regulatory areas.

The platform, which is meant for all stages of drug development, enables companies to submit requests for advice and to share data. The agency said it will offer virtual training in the coming weeks.